Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure\nprophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed\nuninfected (HEU) infants. Materials and Methods. We included PCR-confirmed HEU infants enrolled in a cross-sectional survey\nof mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was\ndetermined by self-report and clinic records. Six-week and 9-month z-scores for weight-for-age (WAZ), weight-for-length (WLZ),\nlength-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF\nexposure using t-tests and multivariate linear regression models. Results. Among 277 mothers who received ART during pregnancy,\n63% initiated ART before pregnancy, of which 89 (32%) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg,
Loading....